Masubuchi Miyako, Ebiike Hirosato, Kawasaki Ken-ichi, Sogabe Satoshi, Morikami Kenji, Shiratori Yasuhiko, Tsujii Shinji, Fujii Toshihiko, Sakata Kiyoaki, Hayase Michiko, Shindoh Hidetoshi, Aoki Yuko, Ohtsuka Tatsuo, Shimma Nobuo
Chugai Pharmaceutical Kamakura Research Center (formerly Nippon Roche Research Center), 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan.
Bioorg Med Chem. 2003 Oct 1;11(20):4463-78. doi: 10.1016/s0968-0896(03)00429-2.
The C-4 side chain modification of lead compound 1 has resulted in the identification of a potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor RO-09-4609, which exhibits antifungal activity against C. albicans in vitro. Further modification of its C-2 substituent has led to the discovery of RO-09-4879, which exhibits antifungal activity in vivo. The drug design is based on X-ray crystal analysis of a CaNmt complex with benzofuran derivative 4a. The optimization incorporates various biological investigations including a quasi in vivo assay and pharmacokinetic study. The computer aided drug design, synthesis, structure-activity relationships, and biological properties of RO-09-4879 are described in detail.
先导化合物1的C-4侧链修饰已导致鉴定出一种强效且选择性的白色念珠菌N-肉豆蔻酰转移酶(CaNmt)抑制剂RO-09-4609,其在体外对白色念珠菌表现出抗真菌活性。对其C-2取代基的进一步修饰导致发现了RO-09-4879,其在体内表现出抗真菌活性。药物设计基于CaNmt与苯并呋喃衍生物4a复合物的X射线晶体分析。优化过程纳入了各种生物学研究,包括准体内试验和药代动力学研究。详细描述了RO-09-4879的计算机辅助药物设计、合成、构效关系和生物学特性。